Alastair and Praveen @PraveenRangan9 are joined by the renowned Dr. Jonathon Leipsic @JonathonLeipsic to discuss plaque characterization and cardiac CT. In this first part of a two part conversation, Dr. Leipsic and our hosts discuss the recent data behind plaque morphology.

Alastair and Praveen are joined by Dr. Charley Taylor to discuss the coronary lumen volume to myocardial mass ratio (V/M), an advanced technique in characterizing coronary physiology from CTA data. Tune in and enjoy! 

Nidhi Madan and Praveen Ranganath continue the conversation on FFRct by dissecting the results of the ADVANCE registry. How can FFRct impact real world decision making? Tune in and find out!

Praveen Ranganath is joined by new voice Nidhi Madan  on this episode reviewing the ins and outs of CT-FFR. Are you curious about where CT-FFR started, how it works, how it was validated, and where it's going next? Well then tune in and enjoy!

Alastair and Praveen continue their discussion on HALT and TAVR in this episode with a breakdown of the recently-published GALILEO-4D CT substudy. What impact does anticoagulation have on HALT? Tune in and find out! 

On this episode, Alastair and Praveen are joined by Dr. Michelle Williams to follow-up a previous episode on adverse plaque features from a subanaylsis of the SCOT-HEART trial. Dr. Williams is one of the SCOT-HEART trial principal investigators and the lead author of the trials' recent adverse plaque subanalysis. Dr. Williams provides her expert insight on the science and future of CT adverse plaque features. Tune in and enjoy!

Link to publication: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044720

Is subclinical valve thrombosis in TAVR really all that bad? Alastair and Praveen dive into structural cardiac CT in this episode focused on the recent PARTNER 3 CT substudy. Tune in and enjoy!

Link to trial publication: https://www.onlinejacc.org/content/75/24/3003

Alastair and Praveen discuss the recently published subanalysis of the SCOT-HEART trial focused on low attenuation noncalcified plaque. What is really more important in the assessment of coronary artery disease: plaque or stenosis? Tune in and find out!

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044720

Building on last episode, Alastair and Praveen dive further into the role of CT and ACS by breaking down the CARMENTA trial. Can we safely defer a trip to the cath lab with a #YesCCT first strategy? Tune in and find out! 

On this episode, Alastair and Praveen talk about how coronary CTA was used for an NSTEMI population in a substudy of the VERDICT trial. Does coronary CTA accurately characterize CAD in certain ACS patients? Tune in and find out!